The kinetoplastid chemotherapy revisited: current drugs, recent advances and future perspectives

dc.centroUniversidad Cardenal Herrera-CEU
dc.contributor.authorCastillo García, Encarnación
dc.contributor.authorDea Ayuela, María Auxiliadora
dc.contributor.authorBolás Fernández, Francisco
dc.contributor.authorRangel, M.
dc.contributor.authorGonzález Rosende, María Eugenia
dc.contributor.otherUCH. Departamento de Farmacia
dc.date.accessioned2024-01-23T09:02:27Z
dc.date.available2024-01-23T09:02:27Z
dc.date.issued2010
dc.descriptionEste recurso no está disponible en acceso abierto por política de la editorial.
dc.description.abstractLeishmaniasis, African sleeping sickness and Chagas disease, caused by the kinetoplastid parasites Leishmania spp, Trypanosoma brucei and Trypanosoma cruzi, respectively, are among the most important parasitic diseases, affecting millions of people and considered to be within the most relevant group of neglected tropical diseases. The main alternative to control such parasitosis is chemotherapy. Nevertheless, the current chemotherapeutic treatments are far from being satisfactory. This review outlines the current understanding of different drugs against leishmaniasis, African sleeping sickness and Chagas disease, their mechanism of action and resistance. Recent approaches in the area of anti-leishmanial and trypanocidal therapies are also enumerated, new modulators from the mode of action, development of new formulations of old drugs, therapeutic switching and “in silico” drug design.es_ES
dc.identifier.citationCastillo, E., Dea-Ayuela, M.A., Bolás-Fernández, F., Rangel, M. & González-Rosende, M.E. (2010). The kinetoplastid chemotherapy revisited: current drugs, recent advances and future perspectives. Current Medicinal Chemistry, vol. 17, i. 33, pp. 4027–4051. DOI: https://doi.org/10.2174/092986710793205345es_ES
dc.identifier.doihttps://doi.org/10.2174/092986710793205345
dc.identifier.issn0929-8673
dc.identifier.issn1875-533X (Electrónico)
dc.identifier.urihttp://hdl.handle.net/10637/15055
dc.language.isoenes_ES
dc.relationUCH. Financiación Autonómica
dc.relationUCH. Financiación Universidad
dc.relationEste artículo de investigación ha sido financiado por la Generalitat Valenciana (AP-116/09) y por la Universidad CEU Cardenal Herrera (PRCEU-UCH08-07).
dc.relation.ispartofCurrent Medicinal Chemistry, vol. 17, i. 33
dc.relation.projectIDAP-116/09
dc.relation.projectIDPRCEU-UCH08-07
dc.rightsrestricted access
dc.rights.cchttps://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.subjectFarmacología
dc.subjectPharmacology
dc.subjectMedicamento
dc.subjectDrugs
dc.subjectTratamiento médico
dc.subjectMedical treatment
dc.subjectEnfermedad transmisible
dc.subjectInfectious diseases
dc.titleThe kinetoplastid chemotherapy revisited: current drugs, recent advances and future perspectiveses_ES
dc.typeArtículoes_ES
dspace.entity.typePublicationes
relation.isAuthorOfPublicationa594bc14-78fb-4463-bb01-204b60f3314e
relation.isAuthorOfPublicationfd42a96f-eb63-4a4e-b34c-68842904b28e
relation.isAuthorOfPublicationf623af41-20d4-43d8-9e2e-dd8d69954b62
relation.isAuthorOfPublication.latestForDiscoverya594bc14-78fb-4463-bb01-204b60f3314e

Files

Original bundle

Now showing 1 - 2 of 2
Thumbnail Image
Name:
Kinetoplastid_Castillo_CMC_2010.jpg
Size:
376.54 KB
Format:
Joint Photographic Experts Group/JPEG File Interchange Format (JFIF)
No Thumbnail Available
Name:
Kinetoplastid_Castillo_CMC_2010.pdf
Size:
456.45 KB
Format:
Adobe Portable Document Format

Collections